BAXTER INTERNATIONAL INC acquires Claris Injectables Limited (Claris)
Snapshot
BAXTER INTERNATIONAL INC acquired Claris Injectables Limited (Claris) for approximately $629 million total cash consideration, net of cash acquired in July 2017. The transaction was structured as all cash. Claris Injectables Limited (Claris) is a Ahmedabad, India-based Generic injectable pharmaceuticals business.
- Acquirer
- BAXTER INTERNATIONAL INC
- Target
- Claris Injectables Limited (Claris)
- Value
- approximately $629 million total cash consideration, net of cash acquired
- Date
- July 2017
- Type
- full acquisition
- Status
- ready
The deal at a glance
About this deal
BAXTER INTERNATIONAL INC acquired Claris Injectables Limited (Claris) for approximately $629 million total cash consideration, net of cash acquired, a transaction completed in July 2017, structured as all cash.
Claris Injectables Limited (Claris) operates in Generic injectable pharmaceuticals, is based in Ahmedabad, India, had revenue of about Contributed $57 million of net sales to Baxter in 2017 (partial year). Claris Injectables Limited, a wholly owned subsidiary of Claris Lifesciences Limited, is a generic injectable pharmaceuticals maker producing essential generic injectable medicines such as anesthesia and analgesics, renal, anti-infectives and critical care products in bags, vials and ampoules.
Through the acquisition, Baxter added capabilities in the production of essential generic injectable medicines, expanding its hospital and pharmacy product portfolio.
Added a sterile generic-injectables manufacturing platform and product portfolio in a fast-growing hospital-pharmaceuticals segment. Integrated into Baxter's pharmaceuticals / hospital products business
No advisory firms have been disclosed for this transaction.